Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC — ELANFIT  

Metastatic or Recurrent Head and Neck Squamous Cell Cancer Clinical Trial

Official title: Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment

Status Completed

Clinical Trial Summary

The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Frailty
• Metastatic or Recurrent Head and Neck Squamous Cell Cancer
• Neoplasms, Squamous Cell
• Recurrence

• NCT number: NCT01864772
• Study type: Interventional
• Source: Groupe Oncologie Radiotherapie Tete et Cou
• Status: Completed
• Phase: Phase 2
• Start date: September 2013
• Completion date: May 26, 2020